NRC Health
NRC Health's revenue fell 4.0% to $137 million in fiscal 2025. Its operating margin was 16.4%, down from 24.6% a year earlier. Free cash flow was $16 million, down 17.9%. It paid out $31 million in dividends and buybacks, 198% of free cash flow. The diluted share count fell 5.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What NRC Health does
NRC Health sells subscription-based tools that help healthcare organizations learn what patients, consumers and employees think. It collects survey feedback and other self-reported information, analyzes it, and gives hospitals and health systems reports and workflow tools to act on it. Its customers are spread across the United States.
It groups its digital solutions in four categories: Patient Experience, Consumer Experience, Employee Experience and Market Experience. They cover patient surveys, including surveys that meet federal CAHPS rules, discharge calls, online reputation and star ratings, employee engagement, and a yearly consumer survey of about 300,000 people. Revenue comes mostly from recurring contracts that customers renew each year. NRC Health says it competes in a market with many rivals and new entrants. Its ten largest customers made up 20% of revenue in 2025.
The company was founded in 1981 and is based in Lincoln, Nebraska. As of December 31, 2025, it had 357 associates, most of whom work remotely.
Its biggest risks, as it describes them
- Customers may not renew contracts, may buy less, or may pay lower prices, and it may lose key customers.
- It faces strong competition and possible price pressure in a crowded market.
- Its customers are all in healthcare, so industry rule changes, downturns and consolidation affect it directly.
- Problems collecting the survey data its business relies on.
- Its principal shareholders effectively control the company.
Income statement
From fiscal 2016 to 2025, net income fell 6.1% a year; the filings' structured data doesn't give diluted earnings per share.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 54 | 25 | 7 | 4 | 4 |
| Debt incl. finance leases | 27 | 22 | 37 | 63 | 79 |
| Net debt (negative means net cash) | −27 | −3 | 30 | 58 | 75 |
| Net debt to EBITDA | — | — | 0.7x | 1.4x | 2.5x |
| Debt to equity | 0.3x | 0.3x | 0.8x | 2.0x | 5.7x |
| Interest coverage | 30.2x | 38.5x | 46.5x | 13.6x | 4.7x |
| Current ratio | 1.8x | 1.3x | 0.7x | 0.6x | 0.6x |
| Quick ratio | 1.8x | 1.3x | 0.7x | 0.6x | 0.6x |
Cash flow
Projections
Project NRC Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $98,160 of NRC Health shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | Shane R HarrisonEVP & Chief Financial Officer | Bought | 8,000 | $12.27 | $98,160 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 8 | 5 of 8 | 5 of 8 |
| Rule of 40 | 13.1% | 9.7% | 7.5% |
| Altman Z'' | 1.45 | 0.88 | 0.03 |
| Accruals ratio | −5.7% | −7.7% | −11.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 6 of 8 | 5 of 8 | 5 of 8 |
Compare
Put NRC Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| NRC Health | FY25 | −4.0% | 16.4% | 11.5% | 16.4% | 2.5x | 5 | |
| CareCloud | FY25 | 8.7% | 9.4% | 19.7% | 21.5% | −0.1x | 5 | Compare |
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 109 | 118 | 120 | 128 | 133 | 148 | 152 | 149 | 143 | 137 |
| Revenue growth | 6.9% | 7.5% | 1.8% | 6.9% | 4.1% | 11.0% | 2.4% | −2.0% | −3.7% | −4.0% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 31 | 34 | 35 | 43 | 43 | 50 | 46 | 40 | 35 | 23 |
| Net income | 20 | 23 | 30 | 32 | 37 | 38 | 32 | 31 | 25 | 12 |
| Diluted EPS (US$) | — | — | — | — | — | — | — | — | — | — |
| Diluted shares (millions) | — | — | — | 26 | 26 | 26 | 25 | 25 | 24 | 22 |
| Cash flow | ||||||||||
| Cash from operations | 27 | 28 | 40 | 41 | 41 | 46 | 36 | 38 | 35 | 26 |
| Capital expenditure | 4 | 5 | 6 | 5 | 4 | 6 | 10 | 16 | 15 | 11 |
| Free cash flow | 23 | 24 | 34 | 36 | 37 | 41 | 26 | 22 | 19 | 16 |
| Dividends paid | 29 | 17 | 17 | 31 | 10 | 9 | 21 | 36 | 12 | 11 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 4 | 28 | 19 | 31 | 20 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 5 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 33 | 35 | 13 | 14 | 35 | 54 | 25 | 7 | 4 | 4 |
| Debt incl. finance leases | 4 | 1 | 39 | 35 | 32 | 27 | 22 | 37 | 63 | 79 |
| Total assets | 121 | 127 | 108 | 111 | 133 | 158 | 130 | 122 | 132 | 135 |
| Total liabilities | 38 | 37 | 89 | 78 | 69 | 72 | 58 | 74 | 101 | 121 |
| Shareholders' equity | 83 | 90 | 19 | 33 | 64 | 85 | 72 | 49 | 31 | 14 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 28.5% | 29.1% | 29.5% | 33.6% | 32.0% | 34.0% | 30.7% | 26.9% | 24.6% | 16.4% |
| Net margin | 18.8% | 19.5% | 25.1% | 25.3% | 28.0% | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% |
| Free cash flow margin | 20.9% | 20.0% | 28.3% | 28.3% | 27.5% | 27.6% | 17.4% | 15.0% | 13.4% | 11.5% |
| Rule of 40 (growth + FCF margin) | 27.8% | 27.5% | 30.1% | 35.3% | 31.6% | 38.6% | 19.9% | 13.1% | 9.7% | 7.5% |
| Return on capital | 44.8% | 41.8% | 60.3% | 69.3% | 66.1% | 64.5% | 54.1% | 41.8% | 31.6% | 16.4% |
| Return on equity | 26.1% | 26.6% | 55.1% | 124.7% | 76.7% | 50.1% | 40.4% | 51.2% | 61.8% | 51.2% |
| Return on assets | 16.5% | 18.5% | 25.5% | 29.6% | 30.5% | 25.8% | 22.1% | 24.5% | 19.4% | 8.7% |
| Net debt to EBITDA | −0.8x | −0.9x | 0.6x | 0.4x | — | — | — | 0.7x | 1.4x | 2.5x |